Dr. Daniel Von Hoff
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
October 01, 2024 08:00 ET | EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
EnGeneIC_Logo.png
EnGeneIC and Singapore Institute of Advanced Medicine Holdings Forge Strategic Partnership to Revolutionise Cancer Treatment in Asia
June 06, 2024 21:13 ET | EnGeneIC
SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) -- EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has...
EnGeneIC_Logo.png
EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeutic
December 07, 2023 19:51 ET | EnGeneIC
EneneIC has been granted Fast Track designation for use of its novel Armed Nanocell Drug Conjugate (ANDC) in PDAC patients.
EnGeneIC_Logo.png
EnGeneIC’s breakthrough Armed Nanocell Drug Conjugate (ANDC) treatment shows promising results in Pancreatic cancer patients who have run out of treatment options
November 26, 2023 23:37 ET | EnGeneIC
SYDNEY and NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- EnGeneIC, a pioneer in personalised cancer therapeutics, announces the publication of its clinical trial results in peer reviewed prestigious...
EnGeneIC_Logo.png
November is Pancreatic Cancer Awareness Month
November 08, 2023 04:00 ET | EnGeneIC
SYDNEY, Australia and NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Pancreatic ductal adenocarcinoma (PDAC), which accounts for >90% of pancreatic tumors, is one of the most lethal malignancies and...
EnGeneIC_Logo.png
EnGeneIC publishes the COVID-EDV vaccine’s novel mechanism of action in a leading Immunology journal
January 31, 2023 13:46 ET | EnGeneIC
Protects against mutant strainsPromotes a long term memory responseNo side effects in healthy volunteersVaccine stored and transported at room temperature with long shelf lifeSeeking...
EnGeneIC_Logo.png
EnGeneIC’s second generation COVID-19 vaccine protects against all variants
June 28, 2022 07:00 ET | EnGeneIC
SYDNEY, Australia, June 28, 2022 (GLOBE NEWSWIRE) -- The world’s first COVID-19 vaccine to offer immunity against all variants is one step closer. Clinical trials have shown the novel vaccine works...
EnGeneIC_Logo.png
Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment
November 30, 2021 07:00 ET | EnGeneIC
SYDNEY, Australia and NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Australian company EnGeneIC has announced a landmark deal with major US biotech ImmunityBio, over a ground-breaking approach to both...
EnGeneIC_Logo.png
Australian biotech, EnGeneIC, develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response
September 07, 2021 22:26 ET | EnGeneIC
Works against mutant strains including DeltaNo need for refrigeration during transport and storage No added stabilisers or chemicals Safety and immune response clinical trial recruiting now in...